Clinical Trial Update: A Study Of Combined C- MET Inhibitor And PAN-HER Inhibitor (PF-02341066 And PF-00299804) In Patients With Non- Small Cell Lung Cancer [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the combination of crizotinib and neratinib in non-small cell lung cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Xalkori (crizotinib) (crizotinib)
• neratinib (neratinib)

Snippet

Sponsor: Pfizer | Conditions: Non Small Cell Lung Cancer | Phase 1 | Status: COMPLETED | Results posted: 2015-03-30